These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7328769)

  • 1. [Relationship between microvascular occlusion-like symptoms and spontaneous platelet aggregation in chronic myeloproliferative diseases (author's transl)].
    Tanoue K; Nakazawa M; Nakamura H; Nagasawa T; Yoda Y; Abe T; Ijima H; Iyori S
    Rinsho Ketsueki; 1981 Jul; 22(7):1123-9. PubMed ID: 7328769
    [No Abstract]   [Full Text] [Related]  

  • 2. [Blood platelet function in chronic myeloid-type diseases. I. Myeloproliferative diseases].
    Cieslar P; Matousová O
    Vnitr Lek; 1987 Nov; 33(11):998-1009. PubMed ID: 3439041
    [No Abstract]   [Full Text] [Related]  

  • 3. [Platelet function in chronic myeloproliferative syndromes associated with thrombocytosis].
    Grebe G; Pereira J; Mezzano D; Legues ME; Aranda E; Lira P
    Rev Med Chil; 1985 Jan; 113(1):32-7. PubMed ID: 4081383
    [No Abstract]   [Full Text] [Related]  

  • 4. [Epinephrine-induced platelet aggregation and alpha-adrenergic receptor in chronic myeloproliferative disorders].
    Nagoya H
    Nihon Ketsueki Gakkai Zasshi; 1984 May; 47(3):772-80. PubMed ID: 6089486
    [No Abstract]   [Full Text] [Related]  

  • 5. Abnormal aggregation and increased size of platelets in myeloproliferative disorders.
    Cortelazzo S; Barbui T; Bassan R; Dini E
    Thromb Haemost; 1980 Jun; 43(2):127-30. PubMed ID: 7455970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hemostasis disorders and their treatment in patients with chronic myeloproliferative diseases].
    Sidorova LD; Arkhipov BF; Degtiareva MM; Barkagan LZ
    Ter Arkh; 1981; 53(9):91-5. PubMed ID: 7302866
    [No Abstract]   [Full Text] [Related]  

  • 7. [Diagnostic significance of B 12 vitamin levels in chronic myelosis (author's transl)].
    Bláha M; Vanásek J; Opltová L; Stríz A; Horna B
    Cas Lek Cesk; 1976 Feb; 115(5):156-8. PubMed ID: 1253221
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hemostatic studies in chronic myeloproliferative disorders: the relation of platelet function, blood coagulation and fibrinolysis with thrombohemorrhagic complication (author's transl)].
    Niikura H
    Nihon Ketsueki Gakkai Zasshi; 1981 May; 44(3):658-74. PubMed ID: 7331700
    [No Abstract]   [Full Text] [Related]  

  • 9. [Beta-thromboglobulin (author's transl)].
    Endo Y
    Rinsho Byori; 1981 Jan; 29(1):20-5. PubMed ID: 6169853
    [No Abstract]   [Full Text] [Related]  

  • 10. [Measurement of spontaneous platelet aggregation by electrical impedance method of whole-blood aggregometer].
    Yonemitsu H
    Rinsho Byori; 1986 Dec; 34(12):1422-6. PubMed ID: 3560473
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro platelet aggregation defects in patients with myeloproliferative disorders and high platelet counts: are they laboratory artefacts?
    Grignani C; Noris P; Tinelli C; Barosi G; Balduini CL
    Platelets; 2009 Mar; 20(2):131-4. PubMed ID: 19235056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes in platelet aggregation in patients with malignant myeloproliferative syndromes].
    Mejía-Soto G; Palafox ST; Linares PG; Anaya-Galindo R
    Rev Invest Clin; 1987; 39(3):227-30. PubMed ID: 3432764
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders.
    Manoharan A; Gemmell R; Hartwell T
    Am J Hematol; 2006 Sep; 81(9):676-83. PubMed ID: 16795055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Platelet defects in chronic myeloproliferative disorders].
    Raszeja-Specht A; Skibowska A; Kabata J; Hellmann A
    Acta Haematol Pol; 1994; 25(3):253-60. PubMed ID: 7992598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro CFU-mix in peripheral blood of myeloproliferative disorders stimulated by serum of aplastic anemia (author's transl)].
    Aoki I; Toyama K; Okamoto S; Young CD
    Rinsho Ketsueki; 1982 Jan; 23(1):46-52. PubMed ID: 6980301
    [No Abstract]   [Full Text] [Related]  

  • 16. [Characteristics of fluorescein angiogram in chronic myeloproliferative disorders].
    Nagasawa N
    Nippon Ganka Gakkai Zasshi; 1984 Jul; 88(7):1035-42. PubMed ID: 6496246
    [No Abstract]   [Full Text] [Related]  

  • 17. Platelet function after busulphan in chronic myeloproliferative disorders.
    Barbui T; Bassan R; Viero P; Cortelazzo S; Dini E
    Haematologica; 1983; 68(4):469-77. PubMed ID: 6414897
    [No Abstract]   [Full Text] [Related]  

  • 18. Circulating progenitor cells in chronic myeloproliferative diseases.
    Rosti V; Massa M
    Haematologica; 2006 Nov; 91(11):1445-7. PubMed ID: 17082003
    [No Abstract]   [Full Text] [Related]  

  • 19. [Chronic neutrophilic leukaemia. Conceptual remarks on a case (author's transl)].
    Sanz MA; Rafecas FJ; Pérez Sirvent ML; Marty ML
    Sangre (Barc); 1979; 24(4):478-81. PubMed ID: 314679
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical significance of platelet aggregation in blood coagulo-fibrinolytic tests].
    Terada H
    Nihon Rinsho; 1989 Dec; 48 Suppl():921-6. PubMed ID: 2516164
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.